Jiangsu Aidea Pharmaceutical Co Ltd Asset Resilience Ratio

Latest as of June 2026: 4.57%

Jiangsu Aidea Pharmaceutical Co Ltd asset resilience ratio. Jiangsu Aidea Pharmaceutical Co Ltd (688488) has an Asset Resilience Ratio of 4.57% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Jiangsu Aidea Pharmaceutical Co Ltd (688488) liquidity interval to measure how many days the company can operate on defensive assets alone.

Liquid Assets

CN¥90.22 Million
≈ $13.20 Million USD Cash + Short-term Investments

Total Assets

CN¥1.98 Billion
≈ $289.01 Million USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of Jiangsu Aidea Pharmaceutical Co Ltd (2020–2025)

Asset resilience ratio of Jiangsu Aidea Pharmaceutical Co Ltd from 2020 to 2025. This chart shows how Jiangsu Aidea Pharmaceutical Co Ltd's Asset Resilience Ratio has changed over time. Read Jiangsu Aidea Pharmaceutical Co Ltd total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down Jiangsu Aidea Pharmaceutical Co Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see how large is Jiangsu Aidea Pharmaceutical Co Ltd's balance sheet.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents CN¥0.00 0%
Short-term Investments CN¥90.22 Million 4.57%
Total Liquid Assets CN¥90.22 Million 4.57%

Asset Resilience Insights

  • Limited Liquidity: Jiangsu Aidea Pharmaceutical Co Ltd maintains only 4.57% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

Jiangsu Aidea Pharmaceutical Co Ltd Industry Peers by Asset Resilience Ratio

Compare Jiangsu Aidea Pharmaceutical Co Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
argenx NV ADR
NASDAQ:ARGX
Biotechnology 15.95%
Tubize-Fin
BR:TUB
Biotechnology 2.50%
Ascendis Pharma AS
NASDAQ:ASND
Biotechnology 0.00%
Summit Therapeutics PLC
NASDAQ:SMMT
Biotechnology 36.07%
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL
Biotechnology 62.31%
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
Biotechnology 0.00%
Verona Pharma PLC ADR
NASDAQ:VRNA
Biotechnology 0.00%
3SBio Inc
F:83B
Biotechnology 10.64%

Jiangsu Aidea Pharmaceutical Co Ltd Asset Resilience Ratio by Year (2020–2025)

Jiangsu Aidea Pharmaceutical Co Ltd asset resilience ratio by year from 2020 to 2025. The table below shows the annual Asset Resilience Ratio data for Jiangsu Aidea Pharmaceutical Co Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 4.19% CN¥80.19 Million
≈ $11.73 Million
CN¥1.91 Billion
≈ $279.87 Million
-1.49pp
2024-12-31 5.68% CN¥106.18 Million
≈ $15.54 Million
CN¥1.87 Billion
≈ $273.58 Million
-6.67pp
2023-12-31 12.35% CN¥215.75 Million
≈ $31.57 Million
CN¥1.75 Billion
≈ $255.58 Million
-8.89pp
2022-12-31 21.24% CN¥351.64 Million
≈ $51.46 Million
CN¥1.66 Billion
≈ $242.21 Million
+9.86pp
2021-12-31 11.38% CN¥163.31 Million
≈ $23.90 Million
CN¥1.43 Billion
≈ $209.93 Million
-25.68pp
2020-12-31 37.07% CN¥536.31 Million
≈ $78.48 Million
CN¥1.45 Billion
≈ $211.72 Million
--
pp = percentage points

About Jiangsu Aidea Pharmaceutical Co Ltd

SHG:688488 China Biotechnology
Market Cap
$724.72 Million
CN¥4.95 Billion CNY
Market Cap Rank
#10025 Global
#2624 in China
Share Price
CN¥11.77
Change (1 day)
-1.92%
52-Week Range
CN¥11.09 - CN¥22.16
All Time High
CN¥42.39
About

Jiangsu Aidea Pharmaceutical Group Co., Ltd. develops, produces, and sells pharmaceutical products in China and internationally. It offers anti-HIV drugs and human-derived proteins. The company also provides anti-virus products, such as ainuovirine tablets; urinary protein products, including crude product/intermediate of ulinastatin, urinary kallidinogenase, and urokinase; sennae folium granules… Read more